CLEVELAND, OH // Sep. 5, 2023 — Journey Biosciences, a digital health company specializing in predictive clinical screenings and expert lab analysis, has been named a “Rising Star” quarterfinalist in the diagnostic platform category for the Digital Health Hub Foundation Digital Health Awards 2023. These awards recognize innovative companies driving significant change in healthcare through digital technologies.
Journey’s flagship solution combines NaviDKD, a clinically validated predictive screening, with the AI-powered intelligence of Compass™ to provide up to 12 years of advanced diabetes-related kidney disease (DKD) detection.
Why this matters:
“We’re honored to be named a quarterfinalist and are excited to advance to the next stage. Thanks to the Digital Health Hub Foundation team for recognizing Journey’s transformative potential in healthcare,” said Adam Graybill, CEO and Co-Founder of Journey Biosciences. “Combined with being named a top 20 device in the Diabetes Center Berne (DCB) 2023 Innovation Challenge, this recognition reinforces our drive to revolutionize how diabetes-related kidney disease is identified and managed.”
"This year has been our most competitive yet as we've received a great surge in submissions, numbering in the thousands, pouring in from companies worldwide. We are so impressed by the pioneering work in digital health happening on a global scale. Congratulations to all of our quarterfinalists on their notable success” said Awards Founder and Chairman Mark Goldstein.
Award details:
Journey joined StartUp Health’s T1D Moonshot earlier this year and is excited to be a HLTH sponsor in the StartUp Health Pavilion.